Progress and remaining challenges for cancer control in Latin America and the Caribbean

K Strasser-Weippl, Y Chavarri-Guerra… - The lancet …, 2015 - thelancet.com
Cancer is one of the leading causes of mortality worldwide, and an increasing threat in low-
income and middle-income countries. Our findings in the 2013 Commission in The Lancet …

Epidemiology and treatment patterns of epithelial ovarian cancer

P Jessmon, T Boulanger, W Zhou… - Expert review of …, 2017 - Taylor & Francis
Introduction: While ovarian cancer (OC) is relatively rare, it remains one of the most fatal
cancers. Lack of robust screening methods for eOC lead to detection of most cases at …

常见妇科三大恶性肿瘤的流行及疾病负担研究现状

陈慧, 周思园, 孙振球 - 中国现代医学杂志, 2015 - cqvip.com
常见妇科三大恶性肿瘤的流行及疾病负担研究现状-[维普网]-仓储式在线作品出版平台-www.cqvip.com
 我的维普 帐户余额 充值记录 下载记录 我的收藏 购物车 充值 客服 首页 | 期刊大全 | 论文选题 …

[HTML][HTML] Economic burden of gynecological cancers in Iran

N Sargazi, R Daroudi, K Zendehdel… - Value in Health …, 2022 - Elsevier
Abstract Background Gynecological cancers (GCs) are an important cause of morbidity and
mortality among women worldwide. The incidence of cancer is increasing in Iran, and …

Glutathione transferase P1: potential therapeutic target in ovarian cancer

P Simic, I Pljesa, L Nejkovic, D Jerotic, V Coric, J Stulic… - Medicina, 2022 - mdpi.com
Chemotherapy resistance of ovarian cancer, regarded as the most lethal malignant
gynecological disease, can be explained by several mechanisms, including increased …

The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study

L Delgado-Ortega, A González-Domínguez… - The European Journal of …, 2019 - Springer
Objective To assess the economic burden of epithelial ovarian cancer (EOC) in incident
patients and the burden by disease stage in Spain. Methods We developed a Markov model …

[HTML][HTML] Cost-effectiveness of neoadjuvant chemotherapy versus primary surgery in elderly patients with advanced ovarian cancer

IB Poonawalla, DR Lairson, W Chan, LB Piller, XL Du - Value in Health, 2015 - Elsevier
Background The use of neoadjuvant chemotherapy (NAC) in the treatment of advanced
ovarian cancer has increased in recent years. There is uncertainty about NAC's …

[HTML][HTML] Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer–ESMO-MCBS scores

KE Broekman, M Jalving, H Van Tinteren… - Cancer treatment …, 2018 - Elsevier
Background The magnitude of clinical benefit scale (MCBS) was introduced by the
European Society of Medical Oncology (ESMO) to quantify the clinical benefit of therapeutic …

[PDF][PDF] Resource use and costs of newly diagnosed cancer initial medical care

A Dagovic, K Matter Walstra, SF Gutzwiller… - Eur J Oncol, 2014 - researchgate.net
Aims: Assessment of direct medical costs of cancer diagnosis and treatment for newly
diagnosed cancer patients; analysis of patterns of medical service utilization; description of …

Macroeconomic policy impact on oncology-related public expenditure in an emerging European market–signs of early recovery

A Dagovic, A Zugic, MB Jakovljevic - Experimental and Applied …, 2015 - sciendo.com
Healthcare financing in Serbia has faced many challenges over the past few decades. One
of the most severe challenges is a global macroeconomic recession whose far-reaching …